{"id":1021509,"date":"2026-11-16T13:33:45","date_gmt":"2026-11-16T18:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/"},"modified":"2026-11-16T13:33:45","modified_gmt":"2026-11-16T18:33:45","slug":"quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/","title":{"rendered":"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory<\/b><\/p>\n<p><i>New Distribution Agreement paves the way for expanded regional access to LucentAD\u00ae Complete<\/i><\/p>\n<p>BILLERICA, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nQuanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lucentdiagnostics.com%2Ftests%2Flucentad-complete%2F&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=LucentAD%26%23174%3B+Complete&amp;index=1&amp;md5=3e95e1975877b0cac14f14bec29ed783\">LucentAD\u00ae Complete<\/a> blood tests to patients across New Jersey and the surrounding area.<\/p>\n<p>\nLucentAD Complete from Quanterix is powered by the SIMOA\u00ae platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer&#8217;s disease, helping provide a more complete picture of disease risk.<\/p>\n<p>\n\u201cSherman Abrams Lab understands the patient&#8217;s needs and shares our commitment to expanding access to advanced diagnostics,\u201d said Everett Cunningham, CEO of Quanterix. \u201cAccess has been one of the biggest barriers standing between blood-based testing and the patients who need it. This partnership is intended to help close the gap and lead to earlier answers and better outcomes for patients and their families.\u201d<\/p>\n<p>\nAccording to the Alzheimer\u2019s Association, more than <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alz.org%2Falzheimers-dementia%2Ffacts-figures&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=676%2C800&amp;index=2&amp;md5=94a51b693ff15eabee3b71cbb9d58dd7\">676,800<\/a> people aged 65 and older are already living with Alzheimer\u2019s disease across NY, NJ, and CT. The new distribution agreement is aimed at expanding access to blood-based testing for people who exhibit some signs or are at risk of Alzheimer&#8217;s Disease although they have not yet been formally diagnosed with unmet clinical needs.<\/p>\n<p>\n\u201cWe are excited to partner with Quanterix to bring this innovative Alzheimer&#8217;s blood testing technology to the physicians and patients we serve,\u201d said Sal Prifitera, Executive Vice President and Chief Business Officer of Sherman Abrams Laboratory. \u201cThis collaboration reflects our continued commitment to advancing diagnostic capabilities, improving access to cutting-edge testing, and helping physicians make more informed decisions for their patients.\u201d<\/p>\n<p>\nThrough the exclusive arrangement, Sherman Abrams will offer LucentAD Complete testing to its extensive network of referring physicians throughout Metro NY\/NJ region, expanding access to innovative blood-based Alzheimer&#8217;s testing and supporting earlier detection and more informed patient care.<\/p>\n<p>\nTo learn more about LucentAD Complete, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lucentdiagnostics.com&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=www.lucentdiagnostics.com&amp;index=3&amp;md5=a47caf8403d2d98ef4cc0e01014a277c\">www.lucentdiagnostics.com<\/a>. To learn more about Sherman Abrams Laboratory, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.shermanabrams.com&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=www.shermanabrams.com&amp;index=4&amp;md5=25914fbb6cf1ba4a9148a1da3cc7e1ec\">www.shermanabrams.com<\/a>.<\/p>\n<p><b>About Quanterix<br \/>\n<br \/><\/b>Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa\u00ae technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company\u00ae, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue \u2013 advancing precision medicine from discovery to diagnostics. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.quanterix.com&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=www.quanterix.com&amp;index=5&amp;md5=673dd0b79b748e34d11a547753058124\">www.quanterix.com<\/a>.<\/p>\n<p><b>About Sherman Abrams<br \/>\n<br \/><\/b>Established in 1964, Sherman Abrams Labs is Brooklyn&#8217;s foremost full service clinical and anatomic pathology laboratory. Community based, it provides laboratory service to its patients, physician offices, nursing homes, adult homes, hospitals, rehabilitation centers, dialysis centers and home-bound patients. Sherman Abrams continues to grow through its focus on offering personalized health care, and heavy investment in state-of-the-art technology and its employees. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.shermanabrams.com%2F&amp;esheet=54640686&amp;newsitemid=20261116941665&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.shermanabrams.com%2F.&amp;index=6&amp;md5=84b814d7b1bafa3b11a1d832c26746fa\">https:\/\/www.shermanabrams.com\/.<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261116941665\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261116941665\/en\/<\/a><\/span><\/p>\n<p><b>Quanterix Media Contact:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:media@quanterix.com\">media@quanterix.com<br \/>\n<\/a><\/p>\n<p><b>Investor Relations Contact:<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:Ir@quanterix.com\">Ir@quanterix.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Neurology Medical Devices Health Genetics<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261116941665\/en\/355264\/3\/Quanterix_Logo_CMYK_Color_viewimage.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory New Distribution Agreement paves the way for expanded regional access to LucentAD\u00ae Complete BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211; Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD\u00ae Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA\u00ae platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer&#8217;s disease, helping provide a more complete picture of disease risk. \u201cSherman Abrams Lab understands the patient&#8217;s needs and shares our commitment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021509","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quanterix Expands Access to Blood-Based Alzheimer&#039;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quanterix Expands Access to Blood-Based Alzheimer&#039;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory New Distribution Agreement paves the way for expanded regional access to LucentAD\u00ae Complete BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211; Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD\u00ae Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA\u00ae platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer&#8217;s disease, helping provide a more complete picture of disease risk. \u201cSherman Abrams Lab understands the patient&#8217;s needs and shares our commitment &hellip; Continue reading &quot;Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T18:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory\",\"datePublished\":\"2026-11-16T18:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/\"},\"wordCount\":614,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/\",\"name\":\"Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T18:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/","og_locale":"en_US","og_type":"article","og_title":"Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk","og_description":"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory New Distribution Agreement paves the way for expanded regional access to LucentAD\u00ae Complete BILLERICA, Mass.&#8211;(BUSINESS WIRE)&#8211; Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD\u00ae Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA\u00ae platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer&#8217;s disease, helping provide a more complete picture of disease risk. \u201cSherman Abrams Lab understands the patient&#8217;s needs and shares our commitment &hellip; Continue reading \"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T18:33:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory","datePublished":"2026-11-16T18:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/"},"wordCount":614,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/","name":"Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T18:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116941665r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quanterix-expands-access-to-blood-based-alzheimers-testing-in-new-jersey-and-surrounding-area-through-exclusive-partnership-with-sherman-abrams-laboratory\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quanterix Expands Access to Blood-Based Alzheimer&#8217;s Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021509"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021509\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}